• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Diabetes therapy >The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus
【24h】

The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus

机译：Alogliptin与磺酰脲类的成本效益与磺胺蛋白的加入治疗患者在不受控制的2型糖尿病患者中

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: ENDURE (ClinicalTrials.gov identifier, NCT00856284), a multicenter, double-blind, active-controlled study of 2639 patients with uncontrolled type 2 diabetes mellitus (T2DM), found that metformin in combination with alogliptin (12.5 and 25 mg doses), when compared to standard add-on therapy (sulfonylurea, SU), exerted sustained antihyperglycemic effects over 2 years. This economic analysis of ENDURE aimed to quantify the relationship between increased glycemic durability and cost-effectiveness of alogliptin in the UK clinical setting, and communicate its sustained glycemic benefit in economic terms. Methods: Using baseline characteristics and treatment effects from the ENDURE trial population, between-group cost-effectiveness analyses compared the combined use of metformin and alogliptin (MET + ALO_(12.5/25)) in patients with inadequately controlled T2DM, as an alternative to metformin and SU (MET + SU). In scenario analyses, an intragroup cost-effectiveness analysis compared MET ? ALO_(12.5/25) with MET + SU; a between-group cost-effectiveness analysis also compared MET + ALO_(12.5/25) versus MET + SU within a subpopulation of patients who achieved HbA1c control (< 7.5%) at 2 years on study drug. Results: Compared with baseline profiles of patients, combination therapies with alogliptin or SU were associated with improvements in length and quality of life and were cost-effective at established norms. Despite increased drug acquisition costs, alogliptin at 12.5 mg and 25 mg doses resulted in greater predicted lifetime quality-adjusted life year (QALY) gains with associated incremental cost-effectiveness ratios (ICERs) of ￡10,959/QALY and ￡7217/QALY compared to SU, respectively. Conclusion: The ENDURE trial and the present cost-effectiveness analysis found that the glycemic durability of alogliptin therapy was associated with improved long-term patient outcomes, QALY gains, and ICERs that were cost-effective when evaluated against standard threshold values. Alogliptin therefore represents a cost-effective treatment alternative to SU as add-on therapy to metformin in patients with poorly managed T2DM. Funding: Takeda Development Centre Europe Ltd.
机译：介绍：忍受（ClinicalTrials.gov标识符，NCT00856284），多中心，双盲，主动控制的2639例不受控制的2型糖尿病患者（T2DM），发现二甲双胍与Alogliptin（12.5和25mg剂量）组合，与标准附加治疗（Sulfonylurea，Su）相比，2年来施加持续的抗血性血糖作用。这种经济分析持久的旨在量化英国临床环境中阿洛术素血糖耐久性和成本效益之间的关系，并在经济方面传达其持续的血糖益处。方法：采用基线特征和治疗效果从持续试验群体，组成本效果分析与患者患者的组合使用与Metformin和Alogliptin（Met + Alo_（12.5 / 25））相比，其替代方案二甲双胍和su（遇到+ su）。在情景分析中，核心属性效果分析比较了相符？ alo_（12.5/25）达到+ su;在研究药物的2年患者的患者的患者亚群中，在群体+ alo（12.5 / 25）之间的患者+ alo_（12.5 / 25）之间进行了+ alo（12.5 / 25）之间的蛋白+α。结果：与患者的基线概况相比，Alogliptin或Su的组合疗法与生命的长度和质量的改善有关，并且在建立的规范中具有成本效益。尽管药物采集成本增加，Alogliptin为12.5毫克和25毫克剂量，导致更大的预测寿命质量调整后的寿命年（QALY）增长，效果有关的增量成本效益比率（ICER）为10,959英镑，而£7217 / QALY。 Su分别。结论：持久试验及目前的成本效益分析发现，在评估标准阈值时，Alogliptin治疗的血糖耐久性与改善的长期患者结果，QALY收益和转换器有关。因此，Alogliptin代表了一种成本效益的治疗方法，作为患者患者患者的成交量含量达到植物患者。资金：Takeda开发中心欧洲有限公司

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号